Even if the Affordable Care Act is ultimately deemed unconstitutional, stakeholders wouldn’t allow the momentum surrounding value-based care models and biosimilars to stall, experts and provider groups said.
A Texas federal judge ruled last week that the Affordable Care Act couldn’t stand without the individual mandate, rendering the entire law unconstitutional. The decision is likely to weave its way up to the Supreme Court. If the decision is upheld, it has the potential to upend efforts to bolster value-based care models instituted under the ACA as well as the pathway for biosimilar drugs.
While many didn’t see the latest ruling coming, policy experts don’t expect U.S. District Judge Reed O’Connor’s decision to stand. Even if it does, the government, providers, insurers, drug manufacturers and other stakeholders will find a way to sustain these programs, industry observers said.